March 17, 2020 09:25 AM EDT
R&D

Safe­ty is­sues force No­vo Nordisk to shut­ter PhI­II he­mo­phil­ia tri­als

John Carroll

Editor & Founder

Five months af­ter rolling out proof-of-con­cept da­ta on their an­ti-tis­sue fac­tor path­way in­hibitor con­cizum­ab, No­vo Nordisk abrupt­ly shut down a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times